{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:30:07Z","timestamp":1794328207763,"version":"4.9.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In the phase 3 POLARIX study, Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) improved progression-free survival (PFS) vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This post hoc subgroup analysis of POLARIX evaluated the efficacy and safety of Pola-R-CHP vs R-CHOP in older patients aged \u226560, \u226565, \u226570, and \u226575 years. As of 15 June 2022 (median follow-up, 40 months), 629 patients aged \u226560 years were included (Pola-R-CHP, n = 311; R-CHOP, n = 318). Clinically meaningful improvements in PFS with Pola-R-CHP vs R-CHOP were observed across all age groups, particularly in patients aged \u226570 years whereby the risk of disease progression, relapse, or death was reduced by 37% (unstratified hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.96). In patients aged \u226560 years, overall survival was similar with Pola-R-CHP vs R-CHOP (unstratified HR, 0. 99; 95% CI, 0.67-1.47). Safety profiles were similar for Pola-R-CHP vs R-CHOP among patients aged \u226560 years, including rates of grade 3 to 4 adverse events (AEs; 62.7% vs 61.5%), grade 3 to 5 infections (15.0% vs 12.9%), and grade 5 AEs (3.6% vs 3.2%); no novel toxicities were reported. Incidence of grade 3 to 4 febrile neutropenia was higher with Pola-R-CHP than R-CHOP (16.3% vs 7.6%), highlighting the importance of granulocyte colony-stimulating factor prophylaxis in older patients receiving Pola-R-CHP. The benefit-risk profile favored Pola-R-CHP vs R-CHOP in older patients with previously untreated DLBCL. This trial was registered at www.ClinicalTrials.gov as #NCT03274492.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014707","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T22:23:57Z","timestamp":1741991037000},"page":"2489-2499","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Subgroup analysis of older patients \u226560 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-0929","authenticated-orcid":false,"given":"Bei","family":"Hu","sequence":"first","affiliation":[{"name":"1Department of Hematologic Oncology, Atrium Health Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Hematology\/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Willamette Valley Cancer Institute and Research Center, Florence, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Prince of Wales Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-0658","authenticated-orcid":false,"given":"Austin","family":"Kim","sequence":"additional","affiliation":[{"name":"7Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4910-476X","authenticated-orcid":false,"given":"Charles","family":"Herbaux","sequence":"additional","affiliation":[{"name":"8Department of Clinical Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Molina","sequence":"additional","affiliation":[{"name":"9Department of Hematology, H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Grenoble, La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"10Department of Hematology\/Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[{"name":"11Department of Oncology, University Hospital of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saibah","family":"Chohan","sequence":"additional","affiliation":[{"name":"12Hoffmann-La Roche Ltd, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha","family":"Kothari","sequence":"additional","affiliation":[{"name":"13Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Lee Batlevi","sequence":"additional","affiliation":[{"name":"13Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7373-362X","authenticated-orcid":false,"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[{"name":"13Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Sahin","sequence":"additional","affiliation":[{"name":"14F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Lee","sequence":"additional","affiliation":[{"name":"13Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sugidono","sequence":"additional","affiliation":[{"name":"13Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Centre Henri-Becquerel and University of Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"4","key":"2025052708470010900_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3324\/haematol.2014.107300","article-title":"Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010","volume":"100","author":"Issa","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"2025052708470010900_bib2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"2025052708470010900_bib3","unstructured":"National Institute of Health and Care Excellence\n          . Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. Accessed 19 December 2024. https:\/\/www.nice.org.uk\/guidance\/ta933."},{"issue":"2","key":"2025052708470010900_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist"},{"key":"2025052708470010900_bib5","doi-asserted-by":"crossref","first-page":"1082293","DOI":"10.3389\/fimmu.2022.1082293","article-title":"Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: a systematic review and network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2025052708470010900_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/10428194.2021.1992762","article-title":"Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities","volume":"63","author":"Puckrin","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025052708470010900_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2025052708470010900_bib8","unstructured":"European Medicines Agency\n          . POLIVY\u00ae summary of product characteristics. Accessed 19 December 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/polivy."},{"key":"2025052708470010900_bib9","volume-title":"POLIVY\u00ae US prescribing information","year":"2023"},{"key":"2025052708470010900_bib10","unstructured":"National Cancer Institute\n          . Common terminology criteria for adverse events (CTCAE) version 4.0. Accessed 19 December 2024. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."},{"issue":"28","key":"2025052708470010900_bib11","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2025052708470010900_bib12","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2025052708470010900_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"issue":"24","key":"2025052708470010900_bib14","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1182\/bloodadvances.2022007609","article-title":"Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial","volume":"6","author":"Camus","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025052708470010900_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-miniCHOP compared with subcutaneous rituximab-miniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025052708470010900_bib16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025052708470010900_bib17","doi-asserted-by":"crossref","first-page":"e91359ec","DOI":"10.1097\/01.HS9.0000967820.91359.ec","article-title":"Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-Pola-mini-CHP AND R-mini-CHOP [abstract]","volume":"7","author":"Jerkeman","year":"2023","journal-title":"HemaSphere"},{"issue":"23","key":"2025052708470010900_bib18","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2025052708470010900_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2026022540","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:00:00Z","timestamp":1794268800000}},{"DOI":"10.1182\/bloodadvances.2026022540","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:00:00Z","timestamp":1793318400000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2489\/2374961\/blooda_adv-2024-014707-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2489\/2374961\/blooda_adv-2024-014707-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:47:13Z","timestamp":1748350033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2489\/536039\/Subgroup-analysis-of-older-patients-60-years-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014707","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,16]]}}}